Cardiac-resynchronization therapy for the prevention of heart-failure events.

By A. Moss, W. Hall, D. Cannom, H. Klein, Mary W. Brown, J. Daubert, N. Estes, E. Foster, H. Greenberg, S. Higgins and 4 more. New England Journal of Medicine, 2009

2,892 citations recorded by the source corpus.

Subfields: Biomedical Engineering, Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/bbd9f8a0f470a4295a3eea6a0ed41021cf2c0e77

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

Citations in the corpus

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013, background): “(Level of Evidence: A for NYHA class III/IV (38,78,116,594); Level of Evidence: B for NYHA class II (595,596)).”
2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). (2013, methodology): “Pre-speciﬁed subgroup analyses of data collected in the MADIT-CRT, REVERSE and Resynchronization–Deﬁbrillation for Ambulatory Heart Failure Trial (RAFT) trials demonstrated that patients with a QRS duration ≥ 150 ms beneﬁted most from CRT. 50,61,62 Meta-analyses using aggregate data from randomized ”
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 (2012, methodology): “† Two key placebo-controlled RCTs randomized 3618 patients with mild (MADIT-CRT, 15% NYHA class I and 85% NYHA class II) to moderately [Resynchronization/Defibrillation for Ambulatory Heart Failure Trial (RAFT), 80% NYHA class II and 20% NYHA class III] symptomatic HF to either optimal medical thera”
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the preventionof sudden cardiac death (2015, positive): “Two controlled trials randomized 3618 patients with mild HF to optimal pharmacological therapy plus an ICD or optimal pharmacological treatment plus CRT-D.327,329 The MADIT-CRT study329 enrolled 1820 patients who were mildly symptomatic (NYHA class I or II) and who had an LVEF ≤30% with a QRS durati”